← boardnext 2028-08
HOWL
Werewolf Therapeutics, Inc.distress 5/10 · elevated risk$0.360%today-83% from 52w high
Oncology 1
Lead: solid tumors · target PD-1
Revenue
pre-revenue
Liquidity
$46M
Runway
0.9 yrs
Shares 1y
+6%
Price & events
-47.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.0%
1D
-0.8%
1W
+0.8%
1M
-57.6%
3M
-45.9%
6M
-73.7%
1Y
-87.6%
2Y
-98.0%
5Y
-97.7%
All
Overview
- Market Cap
- $17.73M
- Enterprise Value
- $3.37M
- Volume
- 3.08K
- 52 Week Range
- $0.31 – $2.19
- Total Shares
- 48.60M
- Float Shares
- 47.91M
- Short %
- 2.11%
- % Held by Insiders
- 5.61%
- % Held by Institutions
- 26.71%
- RVOL
- 0.00x
- Beta
- 0.30
Pipeline stages · 1 programs
WTX-330
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-08 Estimated 50% readout ~2028-09-15 | Phase 1/2 | WTX-330 | Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma | — | active not recruiting |
| 2026-07-01 | Phase 1 | WTX-124, pembrolizumab | Metastatic Solid Tumor, Advanced Solid Tumor | 150 | active not recruiting |
Catalyst news & presentations · 7
- mid-2027Guided 55%regulatory submissionFiled (NDA/BLA)WTX-1011 · IND filing planned.SEC 8-K
- 2026-08-13earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 1WTX-124 · Completion of Phase 1/1b trial and additional data update.SEC 8-K
- second half of 2025readoutPhase 1WTX-124 · Interim data from monotherapy and combination expansion arms, including tolerability, response rate, and durability.SEC 8-K
- first half of 2025readoutPhase 1WTX-124 · Initial efficacy data from monotherapy expansion armsSEC 8-K
- 1H25trial initiationsecondaryPhase 1/2WTX-330 · Enrollment in Phase 1/2 WTX-330 dose and regimen finding studySEC 8-K
- November 9, 2024conferencedata presentationsecondaryPhase 1WTX-330 · Interim safety and efficacy data from Phase 1 clinical trial of WTX-330SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $7 (+1818% upside) · 1 analysts
- 2025-12-19HC Wainwright & Co.Buy
- 2025-11-18B of A SecuritiesBuy
- 2025-08-25B of A SecuritiesBuy
- 2025-08-21JMP SecuritiesMarket Outperform
- 2025-05-09WedbushOutperform
- 2025-03-12WedbushOutperform
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-20HOWL stock trades on fresh data from Werewolf Therapeutics cancer pipeline - Ad-hoc-news.de
- 2026-07-09HOWL stock stays in focus as Werewolf Therapeutics pursues immuno-oncology pipeline - Ad-hoc-news.de
- 2026-07-08Werewolf Therapeutics (HOWL) director-linked funds sell 143,199 shares - Stock Titan
- 2026-07-08Werewolf Therapeutics director Luke Evnin sells $44,749 in stock - Investing.com
- 2026-07-08Form 4 Werewolf Therapeutics Inc For: 8 July By Investing.com - Investing.com Canada
- 2026-07-06[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
- 2026-07-06Werewolf Therapeutics, Inc. SEC Filing (Jul 6, 2026) - Stock Titan
- 2026-07-06Werewolf Therapeutics, Inc. SEC Filing (Jul 6, 2026) - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.